SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Inovio Pharmaceuticals, Inc. – INO
Inovio Pharmaceuticals, Inc. (INO)
NASDAQ:AMEX Investor Relations:
ir.inovio.com/investors/default.aspx
Company Research
Source: GlobeNewswire
NEW YORK, March 10, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether Inovio and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On March 3, 2020, Inovio issued a press release entitled “Inovio Accelerates Timeline for COVID-19 DNA Vaccine INO-4800.” The press release quoted Dr. J. Joseph Kim, Inovio’s President and Chief Financial Officer, stating that Inovio was “the only company with a Phase 2 vaccine for a related coronavirus that causes Middle East Respiratory Syndrome (MERS)” and that “[u]sing our modern DNA medicines platform, we designed our DNA vaccine INO-4800 in three hours after the publicat
Show less
Read more
Impact Snapshot
Event Time:
INO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INO alerts
High impacting Inovio Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
INO
News
- INOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRPPR Newswire
- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) had its price target lowered by analysts at Royal Bank of Canada from $8.00 to $7.00. They now have a "sector perform" rating on the stock.MarketBeat
- INOVIO Reports Inducement Grants Under Inducement PlanPR Newswire
- INOVIO to Present at Upcoming Scientific ConferencesPR Newswire
- INOVIO to Present at Upcoming Scientific ConferencePR Newswire
INO
Earnings
- 8/8/24 - Miss
INO
Sec Filings
- 10/22/24 - Form SC
- 8/13/24 - Form 424B5
- 8/13/24 - Form 8-K
- INO's page on the SEC website